Quotient, a commercial-stage diagnostics company with over 30 years of experience in transfusion diagnostics, has developed a proprietary multiplex microarray technology called MosaiQ that aims to reshape the way diagnostics is practiced. MosaiQ is the world’s first fully automated, consolidated testing platform that offers multiple tests across different modalities, potentially improving clinical practice, increasing efficiencies, and delivering significant workflow improvements and operational cost savings to laboratories around the world. In response to the COVID-19 pandemic, Quotient developed the MosaiQ COVID-19 Antibody Microarray, which is CE marked and has received an Emergency Use Authorization from the U.S. FDA. The COVID-19 antibody test is currently available for distribution in the U.S., the EU, the UK, and Switzerland. Quotient's operations are based in Switzerland, Scotland, and Pennsylvania.
Quotient Limited's ticker is QTNT
The company's shares trade on the NASDAQ stock exchange
They are based in Eysins, Switzerland
There are 201-500 employees working at Quotient Limited
It is http://www.quotientbd.com/
Quotient Limited is in the Healthcare sector
Quotient Limited is in the Diagnostic Substances industry
The following five companies are Quotient Limited's industry peers: